arrow
I

In-Sik Hwang

chungang university
H指数:16
被引数:574

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Potent inhibition of tumor relapse after anti-HER2 affibody tagged with cotinine (switch) plus anti-cotinine switchable CAR T cell therapy by repeated re-injection of the switch

通过反复重新注射开关,用可替宁 (开关) 加抗可替宁可切换CAR T细胞疗法标记的anti-HER2亲和体后,有效抑制肿瘤复发

2024-03-220
PRE
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

靶向CD19近膜域的新型anti-CD19嵌合抗原受体T细胞产品对非霍奇金淋巴瘤的安全性和有效性: 一项首次人体研究

2023-12-098
OAAI
An open label, dose escalation, phase 1 study of AT101, a novel CD19-directed CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma

在复发或难治性b细胞非霍奇金淋巴瘤患者中,针对CD19近膜表位的新型CD19-directed car-t细胞疗法AT101的开放标签,剂量递增,1期研究

2023-04-140
PRE